Use of SGLT2-inhibitors for type 2 diabetes

Use of SGLT2-inhibitors for type 2 diabetes in acute inpatient care

Published: February 2023. Next review: 2028.

This clinical practice guide outlines the safe use of sodium glucose co-transporter2-inhibitor (SGLT2-i) medicines for people with type 2 diabetes receiving acute inpatient care in NSW hospitals.

It aims to reduce the risk of SGLT2-i-induced diabetic ketoacidosis and improve the early recognition and diagnosis of diabetic ketoacidosis that may be euglycaemic.

It covers:

  • when to withhold SGLT2-i medicines
  • restarting SGLT2-i medicines after they have been withheld
  • use of SGLT2-i medicines in the periprocedural period
  • starting SGLT2-i medicines in hospital (in circumstances where this is considered clinically important).

SGLT2-i medicines are not approved for use in type 1 diabetes.

Download the Use of SGLT2-inhibitors for type 2 diabetes in acute inpatient care guide (PDF 341.7 KB)

Diabetes SGLT2 inhibitors - evidence check

Published: March 2023.

SGLT2 inhibitors are one of the newest classes of drugs that are used for blood glucose control in patients with type 2 diabetes. The rapid evidence check informed the guidance provided in the clinical practice guide.

Focusing on people with diabetes in an inpatient setting, the evidence check explored the:

  • safety of the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors
  • existing recommendations regarding the use of SGLT2 inhibitors.

Download the evidence check (PDF 306.3 KB)

Back to top